October 16, 2025
When you talk with Megan Elizabeth, Director of Core Laboratories at Envol Biomedical, you quickly sense both scientific rigor and genuine enthusiasm for advancing preclinical drug development. Having joined the team just three months ago, Megan brings more than a decade of experience across pharma, biotech, and CRO operations — all of which now converge in her leadership of Envol’s formulation, clinical pathology, and bioanalytical labs.
“What makes Envol different is the synergy,” Megan explains. “Our technical team, veterinarians, scientists, and medical staff all work closely together, so everything stays connected — from how the medicine is administered, to how it’s measured, to how the data are interpreted. That integration adds incredible value to the science.”
A Unified Foundation for Robust Science
At Envol Biomedical, the Core Laboratories represent the critical bridge between study design and scientific insight. By combining multiple laboratory disciplines under one roof, Envol ensures that every stage of the study — from formulation to analysis — maintains consistency, control, and continuity.
Megan’s team oversees three main areas:
- Formulations Laboratory – Preparing both test and control articles across delivery methods including oral, IV, and sterile applications. Grounded in GMP principles, this lab ensures clients receive precisely formulated materials that meet strict quality expectations.
- Clinical Pathology Laboratory – Supporting studies through comprehensive clinical chemistry, hematology, coagulation, and urinalysis panels that provide the physiological context behind pharmacology and toxicology data.
- Bioanalytical Laboratory – Delivering PK/TK, PD, biomarker, ADA, and flow cytometry analyses that illuminate how test articles behave in vivo.
Together, these laboratories form the analytical backbone that supports Envol’s broad study portfolio — including pharmacokinetic and metabolic studies, immunogenicity assessments, and inflammatory models — all aligned with the company’s transition toward GLP compliance.
Built on Vertical Integration
Few CROs can claim the vertical integration that defines Envol. Starting with its own in-house colonies and animal care programs, the company built outward — adding state-of-the-art research facilities, imaging technologies, and now fully developed laboratory services.
That integration streamlines client projects and minimizes the operational gaps often seen when labs, in-life teams, and analytical services are split across multiple organizations.
“It’s a holistic model,” Megan notes. “Clients benefit from a cohesive system where every team is communicating — the people who dose the animals are collaborating directly with the scientists who analyze the samples. That connection strengthens both the data and the interpretation.”
Agile, Client-Centered Science
Envol’s Core Laboratories are designed for agility — adapting to meet each sponsor’s needs based on phase, modality, or study complexity. With rapid assay development and fit-for-purpose validation, Megan’s group works with clients to customize methods that are scientifically sound, efficient, and phase-appropriate.
“Our clients often come to us in high-stakes situations,” Megan says. “Many have only one lead asset and limited timelines. Our goal is to collaborate closely, bring maximum value to every study, and ensure that both the science and the animal use are as effective and ethical as possible.”
This adaptability is especially critical as Envol expands its capabilities in GLP-compliant bioanalytics and supports increasingly complex studies in pharmacology, immunology, and molecular biology.
Experience That Elevates Every Study
With her background in immunology drug development, GMP operations, and CRO management, Megan understands the process of “leveling up” — building systems that grow from startup flexibility into regulated, global-scale reliability.
“I’ve worked in environments that had to evolve from nonregulated to regulated,” she says. “I know what it takes to build structure without losing the agility that makes a team successful. Envol has that balance — a strong foundation that’s organically growing in the right direction.”
For clients, that means a partner who not only understands their science, but also the pressures, timelines, and realities of preclinical development.
Driving Discovery Forward
From its formulations to its flow cytometry, Envol Biomedical’s Core Laboratories are more than a collection of capabilities — they’re the engine behind the company’s mission to deliver integrated, high-quality science with speed and precision.
As Megan puts it best:
“It’s exciting to be on the front lines of new technologies — and to know that what we do here is helping sponsors move promising therapies closer to patients.”